Sign inJoin
Company / Finance

Alpha Cognition Inc.

ACOG · NASDAQ

Alpha Cognition has an FDA-approved Alzheimer's pill, early long-term-care launch traction, two PBM agreements, and $66.0 million of year-end cash, but the story depends on ZUNVEYL turning bottle growth into repeat, reimbursed revenue before launch spending, supply risk, customer concentration, and control weaknesses take over.

FollowAdd to WatchlistAsk Question
NASDAQACOGCoverage BootstrapBiopharmaAlzheimer's DiseaseCommercial Launch
Latest ReportMay 13, 2026ACOG: the Alzheimer pill launch racing payer math and a cash clockView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 of 1 reports match
Clear filters
Selected tags
Coverage Bootstrap
Clear tags
Latest Thesis

ACOG: the Alzheimer pill launch racing payer math and a cash clock

Alpha Cognition has an FDA-approved Alzheimer's pill, early long-term-care launch traction, two PBM agreements, and $66.0 million of year-end cash, but the story depends on ZUNVEYL turning bottle growth into repeat, reimbursed revenue before launch spending, supply risk, customer concentration, and control weaknesses take over.

May 13, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Alpha Cognition Inc.the Alzheimer pill launch racing payer math and a cash clockMay 13, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
ACOG: the Alzheimer pill launch racing payer math and a cash clockAlpha Cognition has an FDA-approved Alzheimer's pill, early long-term-care launch traction, two PBM agreements, and $66.0 million of year-end cash, but the story depends on ZUNVEYL turning bottle growth into repeat, reimbursed revenue before launch spending, supply risk, customer concentration, and control weaknesses take over.NASDAQMay 13, 2026Research reportReadSlides